NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

NovoCure Limited

In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on NovoCure, with a price target of $17.00. According to TipRanks...

J.P. Morgan Sticks to Its Hold Rating for NovoCure (NVCR)

An update from NovoCure ( ($NVCR) ) is now available. On June 30, 2026, Novocure announced that its wearable device Optune Pax received a CE Mark f...

Novocure’s Optune Pax Secures CE Mark for Pancreatic Cancer

The latest announcement is out from NovoCure ( ($NVCR) ). On June 17, 2026, Novocure reported topline data from its Phase 3 TRIDENT trial, which te...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVCR	$16.05	+3.22%	719.33K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVCR	$16.05	+3.2%	719.33K
3
4
5
6

NVCR

NVCR

Get NovoCure Limited Data in Excel

Get NovoCure Limited Data in Excel